dermaprazole
/ Baylor College of Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
March 12, 2025
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
(clinicaltrials.gov)
- P1/2 | N=37 | Recruiting | Sponsor: Michelle S Ludwig | N=57 ➔ 37 | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Jan 2025 ➔ Jan 2026
Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
September 23, 2024
Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer
(clinicaltrials.gov)
- P2 | N=6 | Completed | Sponsor: The University of Texas Health Science Center at San Antonio | Active, not recruiting ➔ Completed
Trial completion • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor
July 03, 2024
Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer
(clinicaltrials.gov)
- P2 | N=6 | Active, not recruiting | Sponsor: The University of Texas Health Science Center at San Antonio | Recruiting ➔ Active, not recruiting | N=45 ➔ 6 | Trial completion date: Sep 2028 ➔ Aug 2024 | Trial primary completion date: Sep 2027 ➔ Aug 2024
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor
February 20, 2024
Pumping Up Dermatologic Drug Reformulation: A Novel Phase II/III Clinical Trial of Topically Reformulated Proton-Pump-Inhibitor Esomeprazole for Prevention and Treatment of Radiation Dermatitis in Breast Cancer
(AAD 2024)
- "Our preclinical studies show that the topically reformulated proton-pump-inhibitor (PPI) esomeprazole (Dermaprazole) can effectively treat radiation-induced skin morphea due to its potent anti-inflammatory and anti-fibrotic effects in animal models. Treatment-related adverse effects such as burning, pruritus, tenderness, rash, and other local/systemic reactions will be assessed. The results of this study may directly impact clinical practice and help reduce radiation-related dermatitis while increasing adherence to the prescribed dose of radiotherapy."
Clinical • P2/3 data • Breast Cancer • Dermatitis • Dermatology • Fibrosis • Genetic Disorders • Immunology • Oncology • Pruritus • Scleroderma • Skin Cancer • Solid Tumor • Systemic Sclerosis
January 01, 2024
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
(clinicaltrials.gov)
- P1/2 | N=57 | Recruiting | Sponsor: Michelle S Ludwig
Trial completion date • Trial primary completion date • Breast Cancer • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
April 20, 2023
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
(clinicaltrials.gov)
- P1/2 | N=57 | Recruiting | Sponsor: Michelle S Ludwig | Not yet recruiting ➔ Recruiting
Enrollment open • Breast Cancer • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
February 08, 2023
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
(clinicaltrials.gov)
- P1/2 | N=57 | Not yet recruiting | Sponsor: Michelle S Ludwig | Initiation date: Dec 2022 ➔ Mar 2023
Trial initiation date • Breast Cancer • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
September 16, 2022
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
(clinicaltrials.gov)
- P1/2 | N=57 | Not yet recruiting | Sponsor: Michelle S Ludwig | Initiation date: Jul 2022 ➔ Dec 2022
Trial initiation date • Breast Cancer • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
June 14, 2022
Dermaprazole Cream for Radiation Dermatitis in Definitive Head and Neck Cancer
(clinicaltrials.gov)
- P2 | N=45 | Recruiting | Sponsor: The University of Texas Health Science Center at San Antonio | Trial completion date: Sep 2027 ➔ Sep 2028 | Trial primary completion date: Sep 2026 ➔ Sep 2027
Trial completion date • Trial primary completion date • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor
June 06, 2022
Dermaprazole Cream for Radiation Dermatitis in Definitive Head and Neck Cancer
(clinicaltrials.gov)
- P2 | N=45 | Recruiting | Sponsor: The University of Texas Health Science Center at San Antonio | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatitis • Dermatology • Head and Neck Cancer • Immunology • Oncology • Solid Tumor
1 to 10
Of
10
Go to page
1